here

Transcription

here - WCLC 2015

Monday, September 7, 2015
P1.01
P1.02
P1.03
P1.04
P1.05
P1.06
TREATMENT OF ADVANCED DISEASE – NSCLC
Immunotherapy
EGFR MT
ALK
Clinical Care of Lung Cancer
Chemotherapy Developments
Meta Analyses and Trial Conduct
EGFR WT, Angiogenesis, OMD
New Targets
Trials in Progress
P1.01-001 – P1.01-003
P1.01-004 – P1.01-017
P1.01-018 – P1.01-023
P1.01-019 – P1.01-041
P1.01-042 – P1.01-057
P1.01-058 – P1.01-061
P1.01-062 – P1.01-071
P1.01-072 – P1.01-073
P1.01-074 – P1.01-087
TREATMENT OF LOCALIZED DISEASE – NSCLC
Quality/Prognosis/Survival
Surgery
Chemotherapy in Early Stage Disease
Radiation
P1.02-001 – P1.02-015
P1.02-016 – P1.02-031
P1.02-032 – P1.02-033
P1.02-034 – P1.02-039
TREATMENT OF LOCOREGIONAL DISEASE – NSCLC
Surgery
Chemoradiation
Radiation
Other
P1.03-001 – P1.03-007
P1.03-008 – P1.03-015
P1.03-016 – P1.03-023
P1.03-024 – P1.03-031
BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
KRAS
Pathology
Biology
Preclinical Therapy
P1.04-001 – P1.04-007
P1.04-008 – P1.04-045
P1.04-046 – P1.04-097
P1.04-098 – P1.04-116
PREVENTION AND TOBACCO CONTROL
Prevention and Tobacco Control
P1.05-001 – P1.05-009
SCREENING AND EARLY DETECTION
CT Screening Programs and Imaging
Biomarkers
P1.06-001 – P1.06-005
P1.06-006 – P1.06-012
Risk, Health Care Delivery, Miscellaneous,
Case Reports and Series
Diagnostic Workup
Prognostic Markers
P1.07
SMALL CELL LUNG CANCER
Biology
Extensive Disease
Limited Disease
Prognosis, Epidemiology and Other
P1.06-013 – P1.06-020
P1.06-021 – P1.06-026
P1.06-027 – P1.06-029
P1.07-001 – P1.07-003
P1.07-004 – P1.07-008
P1.07-009 – P1.07-012
P1.07-013 – P1.07-016
P1.08
THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES
Mesothelioma
P1.08-001 – P1.08-018
Other Thoracic Malignancies
P1.08-019 – P1.08-032
Thymoma
P1.08-033 – P1.08-039
P1.09
NURSING AND ALLIED PROFESSIONALS
No Posters on Monday, September 7
P1.10
ADVOCACY
Advocacy
P1.10-001 – P1.10-008
PALLIATIVE AND SUPPORTIVE CARE
Palliative and Supportive Care
P1.11-001 – P1.11-013
COMMUNITY PRACTICE
Community Practice
P1.12-001 – P1.12-011
P1.11
P1.12
Poster Setup Time: 08:30 – 09:30
Poster Take Down Time: 16:45 – 18:30
(Posters not taken down by 18:30 will be discarded by management)
PRESENTING AUTHOR STAND BY TIME
Time in which Poster Presenters remains at his/her poster board and is available to discuss their
research personally with interested delegates.
09:45 – 10:45 and 15:45 – 16:45 (Networking Breaks)
P1.01 TREATMENT OF ADVANCED DISEASE NSCLC
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - IMMUNOTHERAPY
P1.01-001:
Pembrolizumab for Advanced NSCLC: Patterns of Response and Progression
Jenny H. J. Lee, Australia
P1.01-002:
Response Evaluation and Predictors in NSCLC During Treatment with AntiPDL1
Alessandra Bearz, Italy
P1.01-003:
Co-Expression of Programmed Death Ligand-1 (PD-L1) and CD3 in Patients with
EGFR Mutant NSCLC Treated with EGFR Tyrosine Kinase Inhibitors (TKI)
Ross Soo, Singapore
P1.01 TREATMENT OF ADVANCED DISEASE - NSCLC – EGFR MT
P1.01-004:
Updated Results and Efficacy Analysis According to EGFR Mutation Subtypes
for Gefitinib plus Carboplatin and S-1 of the Phase II Trial
Akihiro Tamiya, Japan
P1.01-005:
Early versus Late Brain Metastases in Wild Type and Mutation Positive EGFR
Patients
Cheryl Ho, Canada
P1.01-006:
Targeted Drug Selection for Advanced NSCLC Treatment
Jun Ni, China
P1.01-007:
Treatment with EGFR-TKIs in Non Small Cell Lung Cancer Patients. The Impact
of EGFR Mutations
Teresa Garcia Manrique, Spain
P1.01-008:
Second Line Erlotinib for NSCLC Patients with EGFR Mutation: Our Experience
Simonida Crvenkova, Macedonia
P1.01-009:
Combination of Angiogenesis Inhibitor and EGFR-TKIs in Advanced NSCLC
Patients Who Developed Acquired Resistance
Xia Song, China
P1.01-010:
Development of Skin Rash within the First Week Is a Potential Surrogate
Marker of Effect in Afatinib for EGFR Mutant NSCLC
Kenichiro Kudo, Japan
P1.01-011:
Response to Erlotinib in Metastatic Lung Adenocarcinoma with a Rare Double
Epidermal Growth Factor Receptor (EGFR) Mutation
Syed H. R. Jafri, USA
P1.01-012:
Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural
Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment
Lei Yu, China
P1.01-013:
EGFR Mutations and Targeted Treatment Reverse the Bad Prognosis of Stage
IV NSCLC Associated to Liver Metastasis
Ignacio Gil-Bazo, Spain
P1.01-014:
Long Term Clinical Benefit of EGFR wt in Advanced NSCLC Patients Treated for
Long Time with Salvage Erlotinib. A Retrospective Analysis
Athanasios Kotsakis, Greece
P1.01-015:
Clinical-Pathological and Survival Analysis of Patients with Advanced NSCLC
and EGFR Mutation Treated With a Drug Therapy Anti-T790M
Jesús Corral, Spain
P1.01-016:
Treatment Outcomes among Elderly Lung Cancer Patients > 65 Years following
Clinical Use of EGFR Tyrosine Kinase Inhibitor
Wan-Teck Lim, Singapore
P1.01-017:
Two Cases of NSCLC with EGFR Exon 20 Insertions with Major Clinical
Response to Cetuximab-Containing Therapies
Chad M. Vanderbilt, USA
P1.01 TREATMENT OF ADVANCED DISEASE - NSCLC – ALK
P1.01-018:
Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive
NSCLC Patients
Keith L Davis, USA
P1.01-019:
Czech Experience with Crizotinib in the Personalized Treatment of NSCLC
Vitezslav Kolek, Czech Republic
P1.01-020:
Symptoms of Bone and Liver Metastases in Patients with ALK+ Non-Small Cell
Lung Cancer (NSCLC)
Anand Dalal, USA
P1.01-021:
Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
Liyan Jiang, China
P1.01-022:
Radiologic Features of Advanced ALK-Rearranged Lung Cancer
Kakeru Hisakane, Japan
P1.01-023:
Discrepancy of ALK Status in Lung Adenocarcinoma Subtypes According to the
IALSC/ATS/ERS Classification in Chinese Patients
Shun Lu, China
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC – CLINICAL CARE OF LUNG CANCER
P1.01-024:
Case Report of a Patient with Non-Small Cell Cancer Treated in Two
Consecutive Randomized Clinical Trilas. Safety of Imaging Procedures
Ewa Chmielowska, Poland
P1.01-025:
Radical Resection for Supraclavicular Lymph Node Metastasis (N3-Stage IIIB)
Adenocarcinoma of the Lung
Jun Zhang, China
P1.01-026:
Post-Treatment Effects of Lung Cancer on Spinal Fracture
Malcolm O. Tagbarha, Nigeria
P1.01-027:
Prognostic Impact of Cytological Fluid Tumor Markers in Non-Small Cell Lung
Cancer
Arthur Cho, South Korea
P1.01-028:
Pathological Characteristics of Lung Cancer Patients in Colombian Coffe Zone
Paula Londno, Colombia
P1.01-029:
Dutch Radiotherapy Lung Audit: Results of 2014
Jose Belderbos, Netherlands
P1.01-030:
Curable Bulky T4 Right Lower Lobe Tumours Invading Diaphragm and Liver: A
Distinct Entity?
Noelle O'Rourke, United Kingdom
P1.01-031:
Feasibility of Median Sternotomy Approach for Locally Advanced Lung Cancer
Hiroki Sato, Japan
P1.01-032:
Surgical Resection for Lung Adenocarcinoma after Afatinib Treatment
Hirofumi Suzuki, Japan
P1.01-033:
Multiple Organ Metastasis Could Be Identified as Poor Prognostic Factors for
NSCLC
Zhenrong Zhang, China
P1.01-034:
Is There A "Physician Effect" in Medical Oncology?
Paul Wheatley-Price, Canada
P1.01-035:
Clinico-Epidemiological Features and Survival Outcome in Patients with NSCLC:
Ain Shams Clinical Oncology Department 5-Year Data
Ahmed A. Nagy, Egypt
P1.01-036:
RFA for Palliative Treatment of NSCLC Rib Painful Metastasis: Experience in 12
Patients
Hu Mu, China
P1.01-037:
Successful Treatment of Non-Small Cell Lung Cancer with Erlotinib throughout
Pregnancy
Claire Verschraegen, USA
P1.01-038:
Endosonographic vs Surgical Staging for Mediastinal Nodal Staging of Lung
Cancer: A Systematic Review
Prakash Balakrishnan, New Zealand
P1.01-039:
Lung Cancer in Kidney Transplant Recipients: A Case-Control Retrospective
Study of 30 Patients
Séverine Fraboulet, France
P1.01-040:
Determining Completeness of Case Ascertainment to the Victorian Lung
Cancer Registry: A Quantitative Case Finding Audit
Rob Stirling, Australia
P1.01-041:
Prognostic Significance of CT Emphysema Score in Patients with Advanced
Squamous Cell Carcinoma of the Lung
Young Saing Kim, South Korea
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - CHEMOTHERAPY DEVELOPMENTS
P1.01-042:
Maintenance Therapy with Pemetrexed after Induction Therapy with
Pemetrexed plus Cisplatin for Advanced Pulmonary Adenocarcinoma
Ho-Kee Yum, South Korea
P1.01-043:
Prognostic Factors in the First-Line Chemotherapy of Advanced Non-Squamous
Non-Small Cell Lung Cancer Patients with Performance Status 2
Shinobu Hosokawa, Japan
P1.01-044:
Cost-Effectiveness of Chemotherapy Based on the Tumor Genetic Profile in
Elderly Patients with Advanced Non-Small-Cell Lung Cancer
Silvia Novello, Italy
P1.01-045:
Drug Fever After Cancer Chemotherapy Is Most Commonly Observed on PostTreatment Days 3-4
Minoru Fukuda, Japan
P1.01-046:
Characteristics of Complete Remission Cases in Advanced Non-Small Cell Lung
Cancer
Takuya Aoki, Japan
P1.01-047:
Pemetrexed in Treating Advanced NSCLC
Luis Mas, Peru
P1.01-048:
Cost-Effectiveness of Pemetrexed for Advanced Non-Squamous Non-Small Cell
Lung Cancer (nsNSCLC) in Patients Treated in a Spanish Institution
Xabier Mielgo Rubio, Spain
P1.01-049:
Feasibility of Cisplatin plus Etoposide for Non-Small Cell Lung Cancer
Associated with Interstitial Lung Disease on Chest Computed Tomography
Masafumi Yamaguchi, Japan
P1.01-050:
Clinical Features of Non-Squamous Non-Small-Cell Lung Cancer Patients
Treated with Long-Term Pemetrexed
Kenichiro Hirai, Japan
P1.01-051:
Efficiency of Nab-Paclitaxel as a Late Phase Chemotherapy for NSCLC
Mitsunori Higuchi, Japan
P1.01-052:
Retreatment with Platinum-Based Regimen for Patients with Metastatic
NSCLC Is a Reasonable Therapy
Rachel L. Mitchell, USA
P1.01-053:
Thiol - Disulfide Ratio (TDR) in Blood as a Predictive in Vitro Test for
Individualized Targeted Therapy Choice in Patients with Advanced NSCLC
Oleksandr O. Obodnikov, Ukraine
P1.01-054:
To Analyse the Efficacy and Toxicity Profile of Continuation Maintenance
Pemetrexed in Advanced NSCLC: An Indian Data
Ullas Batra, India
P1.01-055:
Prognostic Impact of KRAS Mutational Status in Patients with Advanced Lung
Adenocarcinoma Receiving First-Line Cytotoxic Chemotherapy
Arpita Desai, USA
P1.01-056:
A Prospective Audit on Toxicity for Platinum-Based Chemotherapy in Stage
IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A West of Scotland Analysis
Clinton W. Ali, United Kingdom
P1.01-057:
Gemcitabine plus Platinum versus Other Platinum Doublets in Squamous
NSCLC
Caicun Zhou, China
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC -META ANALYSES AND TRIAL CONDUCT
P1.01-058:
Impact of Low-Grade Toxicity on Lung Cancer Patient Willingness to Undergo
Treatment with Novel Agents
Emily H. Castellanos, USA
P1.01-059:
Steps to Improve NSCLC Patient Outcomes Utilizing Mobile Apps - Survey
Findings
Corey J. Langer, USA
P1.01-060:
Value Based Health Care Analysis for Lung Cancer Patients
Ben Van Den Borne, Netherlands
P1.01-061:
The Chicago Thoracic Oncology Database Consortium: A Multi-Site Database
Initiative
Brian M. Won, USA
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - EGFT WT, ANGIOGENESIS, OMD
P1.01-062:
Rash as a Marker for the Efficacy of Necitumumab in the SQUIRE Study
Philip Bonomi, USA
P1.01-063:
Efficacy and Safety of Erlotinib in Squamous Cell Lung Cancer
Marko Jakopovic, Croatia
P1.01-064:
A Phase II Study of Gemcitabine-Cisplatin plus Necitumumab for Stage IV SqNSCLC
Jesús Corral, Spain
P1.01-065:
Bevacizumab Combined with Chemotherapy in the Treatment of Advanced
NSCLC Patients
Zhe Liu, China
P1.01-066:
Maintenance Bevacizumab after Chemotherapy with Bevacizumab in First Line
Treatment of Lung Cancer. A Single Institution Experience
Malika Gamaz Bensaou, Algeria
P1.01-067:
Epidermal Growth Factor Receptor Gene Amplification in Patients with
Advanced-Stage NSCLC
Ondrej Fiala, Czech Republic
P1.01-068:
Randomized Trial of Maintenance Chemotherapy Versus SBRT plus
Maintenance Chemotherapy for Advanced NSCLC - Feasibility and Early
Outcomes
Zabi Wardak, USA
P1.01-069:
Reasons for Discontinuation of Treatment with Bevacizumab in Patients with
Non-Progressing NSCLC - Retrospective Study
Peter Berzinec, Slovakia
P1.01-070:
KRAS Mutations: Does It Mean No Erlotinib?
Margarida Dias, Portugal
P1.01-071:
Long-Term Tolerability Among IRESSA Clinical Access Program (ICAP)
Participants in the United States (US)
Fred R. Hirsch, USA
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - NEW TARGETS
P1.01-072:
Targeted Delivery of a Synthetic microRNA-Based Mimic to Treat Thoracic
Cancers
Glen Reid, Australia
P1.01-073:
MET and Invasive Function in NSCLC
Tamara Mirzapoiazova, USA
P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - TRIALS IN PROGRESS
P1.01-074:
Phase III Study of WBRT with or without Erlotinib for Brain Metastasis NSCLC
Zhen-zhou Yang, China
P1.01-075:
Phase III, Randomized, Double-Blind Trial of Bavituximab Plus Docetaxel in
Previously Treated Stage IIIb/IV Non-Squamous NSCLC (SUNRISE)
David R. Spigel, USA
P1.01-076:
TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant
NSCLC
Ross Camidge, USA
P1.01-077:
First-Line Nivolumab + Nab-Paclitaxel + Carboplatin (C) in Advanced NSCLC
Karen Kelly, USA
P1.01-078:
Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1-Strong-Positive
NSCLC
Julie R. Brahmer, USA
P1.01-079:
Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line
Therapy for NSCLC
Shirish Gadgeel, USA
P1.01-080:
Treatment Rationale and Study Design for the Phase 3 JUNIPER Study:
Abemaciclib vs Erlotinib in Patients with Stage IV NSCLC and KRAS Mutation
Jonathan W. Goldman, USA
P1.01-081:
Patritumab Plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung
Cancer: A 2-Part Phase 3 Study (HER3-Lung)
Wallace L. Akerley, USA
P1.01-082:
A Phase III Study of MEDI4736 (M) an Anti-PD-L1 Antibody ± Tremelimumab
(T), vs Standard of Care (SoC), in Patients with Advanced NSCLC (ARCTIC)
David Planchard, France
P1.01-083:
Phase 2 Study of MEDI4736 in Patients with PD-L1+ Locally Advanced or
Metastatic Stage IIIb-IV NSCLC Treated with ≥ 2 Prior Regimens (ATLANTIC)
Marina C. Garassino, Italy
P1.01-084:
A Phase 2 Study of TH-4000 in Patients with EGFR Mutant, T790M-Negative,
Advanced NSCLC Progressing on an EGFR TKI
Stephen V. Liu, USA
P1.01-085:
A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with
ALK+ NSCLC
Alice Shaw, USA
P1.01-086:
TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs
Chemotherapy in NSCLC
James Chih-Hsin Yang, Taiwan
P1.01-087:
A Phase I Study of Chloroquine with Carboplatin and Gemcitabine in Advanced
Solid Tumors and NSCLC
Nagla Abdel Karim, USA
P1.02 TREATMENT OF LOCALIZED DISEASE - NSCLC
P1.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – QUALITY/PROGNOSIS/SURVIVAL
P1.02-001:
Predictive Factors of Distant and Local Recurrence in Patients with Surgically
Resected Stage 1 NSCLC
Shinjiro Mizuguchi, Japan
P1.02-002:
Interstitial Lung Disease (ILD) Associated Cancer Genesis Is Noble Predictor for
Patients with Non-Small Cell Lung Cancer and ILD
Ryo Miyata, Japan
P1.02-003:
Accuracy of Clinical and Pathologic Staging of Non-Small Cell Lung Cancer in a
Residency Education Program
Mariam J. Almarashda, USA
P1.02-004:
Accurate Assessment of Vessel Invasion Using D2-40 and Victoria Blue Predicts
Recurrence in Patients with Pathological Stage I NSCLC
Satoshi Okada, Japan
P1.02-005:
Impact of Postoperative Complications on Cancer Recurrence following Lung
Cancer Surgery
Takashi Nojiri, Japan
P1.02-006:
Visceral Pleural Invasion Was Common in Larger (> 2 cm) Ground Glass
Nodules, but Showed No Aggressive Prognostic Impact
Lilan Zhao, China
P1.02-007:
The Histologic Subtype of Lung Adenocarcinoma Should Not Deter Sublobar
Resection for Patients with Clinical Stage IA Lung Cancer
Mohamed Kamel, USA
P1.02-008:
Diagnostic Molecular Testing in Multiple Lung Cancers
Jarushka Naidoo, USA
P1.02-009:
Prognostic Value of New IASLC/ATS/RES Lung Adenocarcinoma Classification
on Dominate Tumor in Synchronous Multiple Primary Adenocarcinomas
Chien-Sheng Huang, Taiwan
P1.02-010:
What Is the Difference between Lung Cancer and Infectious Lung Disease in
Predicted Postoperative Pulmonary Function after Pneumonectomy?
Takayuki Nakagawa, Japan
P1.02-011:
The Discordance of Two Major Diagnostic Criteria for Chronic Obstructive
Pulmonary Disease Affects Lung Cancer Prognosis after Resection
Masaya Yotsukura, Japan
P1.02-012:
Study for Prognostic Impact of Tumor Volume Instead of Tumor Size for T
Staging in NSCLCancer
Doosang Kim, South Korea
P1.02-013:
The New Interventional Technique by Photodynamic Therapy Using
Composite-Type Optical Fiberscope of 1.0 mm in Diameter
Jitsuo Usuda, Japan
P1.02-014:
Predictive Factors of Postoperative Acute Exacerbation of Interstitial
Pneumonia for Patients with Lung Cancer
Haruhiro Yukiue, Japan
P1.02-015:
Pathological Variables in Resected NSCLC Tumours: Predictors of Survival?
Haider Al-Najjar, United Kingdom
P1.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – SURGERY
P1.02-016:
Prevalence of Preoperative DVT in Japanese Patients Who Underwent
Thoracic Surgery by Intensive Screeng
Toshiki Takemoto, Japan
P1.02-017:
Complications after Lobectomy or Segmentectomy for cT1aN0M0 Non-Small
Cell Lung Cancer
Takashi Ohtsuka, Japan
P1.02-018:
Needlescopic Lobectomy and Segmentectomy for Primary Lung Cancer: Less
Invasive Surgery Using Fine Scope and Forceps
Michihiko Tajiri, Japan
P1.02-019:
Effectiveness of Touch Cytology on the Staple Line in the Assessment of
Resection Margins for Pulmonary Malignant Tumors
Rie Nakahara, Japan
P1.02-020:
Physiological Assessment in Thoracic Surgery for High Risk Patients with Lung
Cancer; How Do International Guidelines Compare?
Haider Al-Najjar, United Kingdom
P1.02-021:
The Feasibility of Fluorescence Image-Guided Surgery for Pulmonary Nodules
Hyun Koo Kim, South Korea
P1.02-022:
Sleeve Lobectomy Is a Safe and Effective Oncologic Procedure: A Single Center
Experience over Three Decades
Luis Carlos Silva Corten, Belgium
P1.02-023:
The Role of Selective EBUS-TBNA Mediastinal Sampling in Early Lung Cancer
Rajaram Burrah, Australia
P1.02-024:
Conditional Survival after Surgical Treatment of Non-Small Cell Lung Cancer
Takayuki Fukui, Japan
P1.02-025:
Complete VATS Resection and Reconstruction of Carina and Trachea for
Malignant or Benign Disease
Jianxing He, China
P1.02-026:
For NSCLC with T3 (Central) Disease, Sleeve Lobectomy or Pneumonectomy?
Qianli Ma, China
P1.02-027:
Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed
Tomography-Assisted Bronchoscopic Metallic Coil Marking
Takanori Miyoshi, Japan
P1.02-028:
Surgical Resection for Sarcomatoid Carcinoma of the Lung
Tarek Kilani, Tunisia
P1.02-029:
Long and Short-Term Predictors of Outcome in Elderly Patients (≥ 75 Years)
Undergoing Lobectomy for Stage I Non-Small Cell Lung Cancer
Takashi Eguchi, USA
P1.02-030:
Effectiveness of Extended Bilateral Superior Mediastinal Lymph Node
Dissection Through a Median Sternotomy in Patients with Left NSCLC
Toshiya Yokota, Japan
P1.02-031:
Wedge Resection for NSCLC: Does Minimally Invasive Surgery Warrant the
Maximum Advantage?
Pietro Bertoglio, Italy
P1.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – CHEMOTHEARPY IN EARLY STAGE DISEASE
P1.02-032:
Randomized Feasibility Study of S-1 for Adjuvant Chemotherapy in
Completely-Resected Stage IA Non-Small-Cell Lung Cancer (SLCG 0701)
Norihito Okumura, Japan
P1.02-033:
Pemetrexed plus Platinum as Adjuvant Therapy in Patients with Resected Lung
Adenocarcinoma and Exploratory Biomarkers Analysis
Bing Xia, China
P1.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – RADIATION
P1.02-034:
Lung v5 Does Not Predict for Lung Toxicity after Fixed-Beam Intensity
Modulated Radiotherapy (IMRT)
Corinne Faivre-Finn, United Kingdom
P1.02-035:
Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative
Body Radiation Therapy and the Dosimetric Correlations
Fen Wang, USA
P1.02-036:
Peripheral Blood Immunophenotype Changes Following Thoracic Stereotactic
Ablative Radiotherapy
Megan E. Daly, USA
P1.02-037:
Thoracic Radiation-Induced Pleural Effusion and Risk Factors in Patients with
Lung Cancer
Feng-Ming (Spring) Kong, USA
P1.02-038:
A Comparison of Stereotactic Body Radiation Therapy vs. No Treatment for
Patients with Early-Stage Non-Small Cell Lung Cancer
Stefan S. Jeppesen, Denmark
P1.02-039:
Stereotactic Radiotherapy as Salvage Treatment after Stereotactic
Radiotherapy or after Operated Non-Small-Cell Lung Cancer
Charlotte Kristiansen, Denmark
P1.03 TREATMENT OF LOCOREGIONAL DISEASE - NSCLC
P1.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - SURGERY
P1.03-001:
Survival of the NSCLC Patients with Clinical Stage IIIA Disease with N2
Involvement: Case-Control Study with Emphasis on Treatment Modality
Ilkka Ilonen, Finland
P1.03-002:
Surgery in Subclassified Stage IIIA-N2 Lung Cancer Improves Survival
Hans-Stefan Hofmann, Germany
P1.03-003:
A Clinicopathological Study of Resected Small-Sized Non-Small Cell Lung
Cancer 2 cm or Less in Diameter with N2 Lymph Node Metastasis
Yasufumi Kato, Japan
P1.03-004:
Occult Primary Non-Small Cell Lung Cancer with Mediastinal Lymph Node
Involvement
Andreas Rimner, USA
P1.03-005:
Bilobectomy for Lung Cancer: Postoperative Results, and Long-Term Outcomes
M Rahouma, USA
P1.03-006:
Survival Analysis of 121 Cases of Stage III A (N2) Non-Small Cell Lung Cancer
Treated with Surgery Resection
Hao Fu, China
P1.03-007:
Prognosis of Microscopic Residual Disease (R1) at Different Resection Margins
and Efficacy of Adjuvant Therapy
Masato Chiba, Japan
P1.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - CHEMORADIATION
P1.03-008:
Weekly Carboplatin/Gemcitabine + Concurrent Thoracic RT Followed by
Consolidation Carboplatin/Gemcitabine for Inoperable Stage III NSCLC
Manuel Domine, Spain
P1.03-009:
Integration of Chemoradiotherapy in a Single Facility: Impact on Outcomes for
Locally Advanced Non-Small Cell Lung Cancer
Roy H. Decker, USA
P1.03-010:
Adjuvant Chemotherapy plus Radiotherapy is Superior to Chemotherapy in
Surgically Treated IIIA N2 Non-Small-Cell Lung Cancer
Xiao-Ling Xu, China
P1.03-011:
Standard Pre-Hydration May Compromise Treatment Outcome of CRT with
Low-Dose Cisplatin
Else Aalbersberg, Netherlands
P1.03-012:
Combined Effects of SAHA and Cisplatin on Radiation Sensitivity and Cancer
Cell Invasion in NSCLC
Shirong Zhang, China
P1.03-013:
Clinical Characteristics and Survival in Stage IIIA NSCLC Patients Treated with
Neoadjuvant Chemotherapy and Surgery
Narjust Duma, USA
P1.03-014:
Is Concomitant Chemoradiotherapy Feasible for Patients with NSCLC Stage III
A/B?
Femke S. Van Der Meer, Netherlands
P1.03-015:
Safety and Effectiveness of Chemo-Radiotherapy with Weekly Nab Paclitaxel
plus Carboplatin in Locally Advanced Non-Small Cell Lung Cancer
Toshiyuki Sawa, Japan
P1.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - RADIATION
P1.03-016:
Clinical Outcome of Hybrid-Volumetric Arc Therapy (H-VMAT) for Advanced
Inoperable Non-Small Cell Lung Cancer (NSCLC)
Oscar S.H. Chan, Hong Kong
P1.03-017:
Radiation Dose-Related Lymphopenia as an Outcome Predictor in Stage III
NSCLC Patients Treated with Chemoradiation
Nagla Abdel-Karim, USA
P1.03-018:
International Patterns of Radiotherapy Practice for Non-Small Cell Lung Cancer
Shalini K. Vinod, Australia
P1.03-019:
NTCP-Models for Esophagitis with Dose-Differentiated-Radiotherapy (DARTBid)
Franz Zehentmayr, Argentina
P1.03-020:
IMRT Improves Survival in Locally Advanced NSCLC (LA-NSCLC) Receiving
Definitive Radiotherapy: A Population Based Time-Trend Analysis
Luhua (Jingbo) Wang, China
P1.03-021:
Lung Damage Quantification on CT Scans Strengthens Radiation-Induced Lung
Toxicity Prediction Models
Dirk De Ruysscher, Belgium
P1.03-022:
The Effect of Adaptive Planning on Target and Critical Structures During
Radiation Treatment for Locally Advanced Lung Cancer
Hale B. Caglar, Turkey
P1.03-023:
Changes in Pulmonary Function after Stereotactic Body Radiotherapy and
after Surgery for Stage I and II Non-Small-Cell Lung Cancer
Leonie Alberts, Netherlands
P1.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - OTHER
P1.03-024:
Comparison of Prognosis Between Patients with Solitary Lung
Adenocarcinoma and With Multiple Primary Cancers Including Lung
Adenocarcinoma
Sukki Cho, South Korea
P1.03-025:
Relation of Visceral Pleura Invasion with Hilar Lymph Node Involvement and
Survival in Primary Lung Cancer
Serhan Tanju, Turkey
P1.03-026:
Prognostic Value of Pre-Treatment Neutrophil:Lymphocyte Ratio and
Platelet:Lymphocyte Ratio in Stage III NSCLC
Tithi Biswas, USA
P1.03-027:
Factors Predicting Lymph Node Metastasis in Resected Lung Adenocarcinoma
of 2cm or Smaller
Jung-Jyh Hung, Taiwan
P1.03-028:
Multicenter Study of the Usefulness of FDG-PET as a Predictor of the
Clinicopathological Characteristics and Prognosis of Lung Cancer
Norihiko Ikeda, Japan
P1.03-029:
Obesity Is Associated with Long-Term Improved Survival in Definitively
Treated Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
Vincent K. Lam, USA
P1.03-030:
Marital Status Is Strongly Prognostic and Associated with More Favorable
Nutritional Status in Locally Advanced Non-Small Cell Lung Cancer
Josephine L. Feliciano, USA
P1.03-031:
Concurrent Chemoradiotherapy Using Advanced Radiotherapy Technologies
for Inoperable Stage III Non-Small-Cell Lung Cancer
Y C. Li, China
P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING - KRAS
P1.04-001:
MET/RON Inhibition in KRAS Mutated Non Small Cell Lung Cancer
Sravya Tumuluru, USA
P1.04-002:
Protein Signaling Analysis of KRAS Mutant Lung Adenocarcionomas Reveals
Variable MAPK and mTOR Pathway Activation
Elisa Baldelli, USA
P1.04-003:
Metastatic Site-Specific Variation of KRAS Status in Lung Adenocarcinoma
Balazs Hegedus, Hungary
P1.04-004:
Inhibition of Telomerase Activity Suppresses Kras Mutation-Induced Lung
Carcinogenesis and Chemoresistance
Bin Zhang, China
P1.04-005:
Concurrent EGFR and ALK Mutations in KRAS-Mutant Lung Adenocarcinomas
and Their Clinical Behavior
Kevin C. Wood, USA
P1.04-006:
Prognostic and Predictive Role of KRAS-Mutations in Patients with Advanced
Non-Squmous Non-Small-Cell Lung Cancer (NS-NSCLC)
Javier Garde-Noguera, Spain
P1.04-007:
KRAS Mutations in Lung Cancer: Prevalence and Outcomes
Margarida Dias, Portugal
P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING - PATHOLOGY
P1.04-008:
Tissue Hyaluronan and Its Relationship with Angiogenesis Are Indicators of
Lung Cancer Malignancy
Maristela P. Rangel, Brazil
P1.04-009:
Max Collapse and Fibrosis below 5 cm Predict the Prognosis of pT1 Lepidic
Predominant Adenocarcinoma
Masahito Naito, Japan
P1.04-010:
Pilot Internet Survey of Interobserver Variability in Pathology Diagnoses of
Multiple Tumor Nodules
Wilbur A. Franklin, USA
P1.04-011:
Intraoperative Diagnosis of Lymph Node Metastasis Using a RapidImmunohistochemical (R-IHC) Staining Method in Non-Small Cell Lung Cancer
Hayato Konno, Japan
P1.04-012:
Using Computed Tomography Scans to Assess the Histology of Malignant
Pleural Mesothelioma
Samuel Armato, USA
P1.04-013:
Clinicopathological Characteristics of Lung Cancer with Combined Pulmonary
Fibrosis and Emphysema
Akihiko Yoshizawa, Japan
P1.04-014:
Clinicopathologic Significance of Epithelio-Mesenchymal Transition in Human
Lung Adenocarcinoma
Toshi Menju, Japan
P1.04-015:
Pleomorphic Carcinoma of the Lung: A Clinicopathologic Study of 23 Resected
Cases
Dai Sonoda, Japan
P1.04-016:
Assessment of the Adequacy of Tissue Diagnosis by EBUS in Relation to the
PET Scan and the Operator's Experience
Nagla Abdel Karim, USA
P1.04-017:
Pulmonary Lymphoepithelial-Like Carcinoma: A Surveillance, Epidemiology,
and End Results Database Analysis
Jiaxi He, China
P1.04-018:
The Value of Histopathological Examination for Bronchoscopic Ultrasound
Guided Fine-Needle Aspiration in Diagnosis of Lung Cancer Subtypes
Tõnu Vanakesa, Estonia
P1.04-019:
A Comparative Study of Micropapillary Pattern and Computed Tomographic
Findings in the Patients with Small Lung Adenocarcinoma (≤ 2cm)
Jun-ichi Nitadori, Japan
P1.04-020:
Adenocarcinoma Metastatic Gastrointestinal Origin and Lung Squamous
Carcinoma Associated with HIV Disease: Case Report
Liliana Fernandez, Colombia
P1.04-021:
No MAML2 Gene Alteration Found in Ciliated Muconodular Papillary Tumor of
Lung; Genetic Difference from Mucoepidermoid Carcinoma
Noriko Motoi, Japan
P1.04-022:
Prognostic Significance of Solid or Micropapillary Component in Pulmonary
Invasive Adenocarcinoma Measuring ≦ 3cm
Yuki Matsuoka, Japan
P1.04-023:
Primary Adenocarcinoma in the Lung Reclassified - Histological Subtypes and
Outcome
Tomas Gudbjartsson, Iceland
P1.04-024:
When Bone Starts Growing in the Lung: A Case Series of Pulmonary
Ossifications
Paul Van Schil, Belgium
P1.04-025:
Lung Cancer Incidence by Histology, Gender, Race/Ethnicity and
Socioeconomic Status
Manali I. Patel, USA
P1.04-026:
Lung Cancer Patients Who 'Relapse' After Primary Treatment May Have ogy or
No Malignancy
Noelle O'Rourke, United Kingdom
P1.04-027:
The Expression of Fibroblast Activation Protein (FAP) in Human Lung Cancer
Tissues and Its Clinical Significance
Hua Shi, China
P1.04-028:
High Vimentin Expression in Micropapillary Component of Lung
Adenocarcinomas
Hiroyasu Nakashima, Japan
P1.04-029:
Detection of Sputum Cofilin-1 Protein for Diagnosis of Human Non-Small Cell
Lung Carcinomas
Vera L. Capelozzi, Brazil
P1.04-030:
Intra-Operative Pleural Lavage Cytology after Thoracotomy for Lung Cancer
Masatoshi Kakihana, Japan
P1.04-031:
The Changing Anatomic Position of Squamous Cell Carcinoma of the Lung - A
New Conundrum
Manasa Vulchi, USA
P1.04-032:
Clinical and Pathological Characterization of Long-Term Survivors with
Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid
Maria Eugenia Olmedo, Spain
P1.04-033:
Case of a Patient Who Underwent Right Middle Lobectomy of Lung
Adenocarcinoma with Histological Characteristics Similar to Papillary
Adenoma
Masato Watanabe, Japan
P1.04-034:
A Case of Fetal Lung Interstitial Tumor (FLIT) in a Neonate
Akiteru Goto, Japan
P1.04-035:
Clinicopathologic and Biological Characteristics of Young Age Non-Small Cell
Lung Cancer
Tatsuo Ohira, Japan
P1.04-036:
Primary Pulmonary Melanoma: A Report of Two Cases
Mototsugu Watanabe, Japan
P1.04-037:
Lung and Hypopharyngeal Angiosarcoma (AS) in a Renal Transplant Patient:
Case Report
P1.04-038:
Endobronchial Ultrasound Guided Transbronchial Fine Needle Aspiration
Cytology (EBUS-TBNA) for Peribronchial Mediastinal Tumor
Mitsutoshi Shiba, Japan
P1.04-039:
Ex-Vivo Artifacts and Histopathological Pitfalls in the Lung
Erik Thunnissen, Netherlands
P1.04-040:
Stage I Adenocarcinoma According to the 2011 IASLC/ ATS/ ERS: Case Series
from Brazil
André Luiz C. Trajano, Brazil
P1.04-041:
Synchronous Lung Cancers, Squamous Cell and Adenocarcinoma Coexistence,
Case Report
Nesrin Ocal, Turkey
P1.04-042:
Diagnostic Role of Immunocytochemistry in Malignant Pleural Mesothelioma
Nguyen S. Lam, Vietnam
P1.04-043:
Pulmonary Lepidic Adenocarcinoma in a Patient with Prior Diagnosis of Breast
Cancer: Case Report
P1.04-044:
Local Diagnostic Practices for Advanced Non-Small-Cell Lung Cancer in AsiaPacific and Russia: IGNITE Study
Martin Reck, Germany
P1.04-045:
Software Support for Combined Staging of Lung Cancer in CT, Functional MRI
and Pathology
Hendrik O. A. Laue, Germany
P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING - BIOLOGY
P1.04-046:
MFN2 Regulates Lung Adenocarcinoma Cell Proliferation and Invasion
Baohui Han, China
P1.04-047:
The Inhibitory Effects of CDK4 and MDM2 on Migration and Invasion in Human
Non-Small Cell Lung Cancer Cells
Soojeong Kang, USA
P1.04-048:
DNA Demethylation Related Hypoxia-Induced Stem-Like Properties in Lung
Cancer
ChanKwon Park, South Korea
P1.04-049:
The MRE11/RAD50/NBS1 Complex Was Impaired in Lung Cancer from
Chromate-Exposed Workers
Kazuya Kondo, Japan
P1.04-050:
COX-2 Genetic Variants Influence Intratumoral Infiltration of Foxp-3-Positive
Regulatory T Cells in Non-Small Cell Lung Cancer
Masao Nakata, Japan
P1.04-051:
C. Elegans, an in Vivo Model for Lung Cancer: Effect of Chronic Exposure of
Nicotine on Specific Mutants Relevant to Lung Cancer
Jacob J. Riehm, USA
P1.04-052:
TGF-β Induced EMT and Stem-Like Characteristics in Lung Cancer
Seung Joon Kim, South Korea
P1.04-053:
Characterization of Invasive Cancer Cells and Potential Therapeutic Effect of
Suberoylanilide Hydroxamic Acid on Human Lung Cancer Metastasis
Shirong Zhang, China
P1.04-054:
Mitochondrial Status in Peripheral Blood Mononuclear Cells in Relation to
Cognitive Impairment in Lung Cancer Patients
Rodryg Ramlau, Poland
P1.04-055:
Fibroblast-Dependent Cancer Cell Invasion: Analysis of Cancer-Associated
Fibroblasts That Remodel the Extracellular Matrix
Shinya Neri, Japan
P1.04-056:
Use of Pooled shRNA Synthetic Lethal Screens within an In Vivo Murine Model
to Identify Microenvironment-Dependent Lung Cancer Genes
Nathaniel R. Little, USA
P1.04-057:
Wnt Signaling Regulates Cancer Stem Cell in Lung Cancer SPC-A1 Cells
Baohui Han, China
P1.04-058:
Inhibition of ERK1/2 Down-Regulates the Hippo/YAP Signaling Pathway in
Human NSCLC Cells
David Jablons, USA
P1.04-059:
The Role of Histone Methyltransferases G9a/Glp in Mouse Lung Tumor
Propagating Cells and Lung Stem Cells
Samuel Rowbotham, USA
P1.04-060:
Pathways Involved in Lung Adenocarcinomas, - Integrated Analyses on
Methylation and mRNA Data
Vilde D. Haakensen, Norway
P1.04-061:
Comparison of MET Expression in Primary and Corresponding Nodal and
Distant Metastases in Non-Small Cell Lung Cancer (NSCLC)
Paul Mitchell, Australia
P1.04-062:
Phagocytic Behaviour in Lung Adenocarcinoma Cells: Clinical Implications and
Cellular Mechanisms
John Le Quesne, United Kingdom
P1.04-063:
Exposure to IL-1β Leads to EMT via Distinct Mechanisms in Acute and Chronic
Inflammation in NSCLC
Rui Li, USA
P1.04-064:
2'-Hydroxyflavanone Inhibits Lung Cancer Growth by Inhibiting Tumor Cell
Proliferation and Angiogenesis
David Berz, USA
P1.04-065:
Cyclin-Dependent kinase11 (CDK11) Is Crucial for Growth of Lung Cancer Cells
Tomohiko Kakumu, Japan
P1.04-066:
Site-Selected Chromatin-Immunoprecipitation (ChIP) Analysis by Laser
Captured Microdissection
Shingo Sakashita, Japan
P1.04-067:
Mitochondrial Respiration Capacity and Sensitivity to Glycolysis Blockade in
Lung Cancer
Maya Ilouze, Israel
P1.04-068:
Protein Tyrosine Kinase 7 Plays a Tumor Suppressor Role by Inhibiting ERK and
Akt Phosphorylation in Lung Cancer
Haewon Lee, South Korea
P1.04-069:
LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-Small Cell Lung
Cancer Plasticity and Therapeutic Response
Xiangkun Han, China
P1.04-070:
Silencing of Rac3 Inhibits Proliferation and Induces Apoptosis of Human Lung
Cancer Cells
Hongxu Liu, China
P1.04-071:
Inhibition of EGFR Lysosomal Degradation in Lung Adenocarcinoma by
Ubiquitin-Specific Protease 8 and Stratifin
Yun-Jung Kim, Japan
P1.04-072:
Gene-Smoking Interactions in Lung Cancer Etiology
Christopher I. Amos, USA
P1.04-073:
The Role of the Stress-Response to a Lung Cancer Diagnosis in Disease
Progression
Hronn Hardardottir, Iceland
P1.04-074:
ITPKA Expression in Lung and Other Cancers, Regulated via Gene Body
Methylation, Functions as an Oncogene
Adi F. Gazdar, USA
P1.04-075:
Kynurenine Pathway Activity in Peripheral Blood Mononuclear Cells and
Cognitive Functions in Lung Cancer Patients
Rodryg Ramlau, Poland
P1.04-076:
CDCA3 Is a Novel Cell Cycle Regulator in Lung Cancer
Kenneth J. O'Byrne, Australia
P1.04-077:
KIF5B-RET Fusion Kinase Promotes Cell Invasion and Migration Which Can Be
Suppressed by RET Inhibitors
Jianhua Chang, China
P1.04-078:
Induction of Achaete-Scute Homologue 1 (ASCL1) by Cigarette Smoke
Condensate in A549 Cells
Michael H. Lee, USA
P1.04-079:
RBM5-Wnt/β-Catenin Signaling in Cigarette Smoke PM 2.5 Induced Alveolar
Epithelial Injury and Its Molecular Mechanism
Zhang Jie, China
P1.04-080:
miR-326 Is Down-Regulated in Non-Small Cell Lung Cancer and Targets NFIB, a
Lung Developmental Gene: A Pilot Study
Deepali Jain, India
P1.04-081:
Expression of PPAR-γ Ligand in Lung Cancer and Its Effect on the Apoptosis of
Lung Cancer
Qiuping Luo, China
P1.04-082:
Anti-Neoplastic Effects of 15(S)-HETE and 13(S)-HODE in Lung Cancer
George G. Chen, China
P1.04-083:
The Metastasis-Related Noncoding RNA Expression Profile and LncRNA
LOC101448202 Induces 95D Cell Migration and Tumor Growth
Shuanying Yang, China
P1.04-084:
Ubiquitin Protein Ligase E3C Promotes Growth and Metastasis of Non-Small
Cell Lung Cancer
Jie Gu, China
P1.04-085:
The Role and Potential Mechanisms of LncRNA-TATDN1 in the Metastasis and
Invasion of 95D Cell
P1.04-086:
Dopamine D2 Receptor Agonists Inhibit Lung Cancer Progression by Reducing
Angiogenesis and Tumor Infiltrating Myeloid Derived Suppressor Cells
Luke H. Hoeppner, USA
P1.04-087:
The Role and Mechanism of Twist1 in Non-Small Cell Lung Cancer
Pathogenesis
Yong Song, China
P1.04-088:
Lung Cancer Cells Can Alter the Behaviour of Normal Bronchial Epithelial Cells
Through Multiple Mechanisms
Kenneth J O'Byrne, Australia
P1.04-089:
MicroRNA miR-615-3p and let-7b Targets Multiple Key Pathways
Overexpressed in Lung Adenocarcinoma
Oluf D. Røe, Norway
P1.04-090:
Roles of MLF1IP in the Proliferation of Lung Adenocarcinoma Cells
Baohui Han, China
P1.04-091:
Biological Significance of CHK2 Gene Expression in Lung Adenocarcinoma
Tatsuro Okamoto, Japan
P1.04-092:
LKB1 Inactivation Confers Human Lung Adenocarcinoma with Strong Plasticity
for Squamous Transdifferentiation
Xiangkun Han, China
P1.04-093:
CCNY2 Promotes Lung Cancer Cell Migration and Invasion via Regulating FActin Expression
Wentao Yue, China
P1.04-094:
NT5E(CD73) Is a Target of miR-30a-5p and Plays a Critical Role in Non-Small
Lung Cancer
Zeyi Liu, China
P1.04-095:
Integrin a11b1 Regulates Cancer Stromal Stiffness and Promotes
Tumorigenicity and Metastasis in Non-Small Cell Lung Cancer
Roya Navab, Canada
P1.04-096:
Second Tumors in Lung Cancer (LC) Patients. Should We Think About This Issue
in Long Term Survival Setting?
Norberto Olguin, Argentina
P1.04-097:
Genome-Wide Methylome Alterations in Lung Cancer
Simon D. Spivack, USA
P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING – PRECLINICAL THERAPY
P1.04-098:
Mithramycin Is a Potential Therapeutic Agent for Elimination of Stem-Like
Cells in Lung Cancer
Haobin Chen, USA
P1.04-099:
Wnt Blockers Inhibit the Proliferation of Lung Cancer Stem Cells
Baohui Han, China
P1.04-100:
Combination of Pitavastatin and Erlotinib Induces Apoptosis and Growth
Arrest in Non-Small Cell Lung Cancer (NSCLC)-Celllines
Christoph Minichsdorfer, Argentina
P1.04-101:
Utility of Patient-Derived Cell Line Models Using Conditional Reprogramming
for in Vitro Pharmacogenomics Platform
Hyun Chang, South Korea
P1.04-102:
Ex Vivo 4D Lung Cancer Model CTCs Show Resistance to Chemotherapeutic
Drugs
Dhruva K. Mishra, USA
P1.04-103:
Oncolytic Virus Therapy for Lung Cancers Using a Genetically Engineered
Oncolytic Herpes Simplex Virus Type 1 G47?
Yoshinori Sakata, Japan
P1.04-104:
Lung Cancer Patients Derived Xenografts: Prospective Molecular Profiling and
Potential Evaluation of Drug Resistance
P1.04-105:
The Development and Assessment of Advanced Cellular Models for the Study
of Non-Small Cell Lung Cancer
Anne-Marie Baird, Australia
P1.04-106:
Granulocyte Colony-Stimulating Factor Enhances the Anticancer Effects of
Cisplatin Against Lung Cancer by Promoting Angiogenesis
Yasushi Ohno, Japan
P1.04-107:
Prediction of Molecular Tageting Drugs' Sensitivity Enabled by In-Vitro Drug
Sensitivity Tests for Surgically Resected Lung Cancer
Ryohei Miyazaki, Japan
P1.04-108:
Non-Invasive Assessment of Cisplatin and Erlotinib Efficacy in Lung Cancer by
Monitoring an Orthotopic SCID Mouse Model with Computed Tomography
Tamaki Otani, Japan
P1.04-109:
Antitumor Efficacy of Histone Deacetylase Inhibitor or in Combination with
EGFR-TKI in Non-Small Cell Lung Cancer Cell Lines
Xiaohong Han, China
P1.04-110:
Use of Blood Outgrowth Endothelial Cells as a Carrier of Oncolytic Vesicular
Stomatitis Virus-Interferon Beta in Treating Metastatic NSCLC
Manish Patel, USA
P1.04-111:
Establishing a Mouse Model for Radiation-Induced Esophagitis
Moon-June Cho, South Korea
P1.04-112:
Rapamycin Attenuated Epithelial-Mesenchymal Transition in Lung Cancer Cells
Lianjun Lin, China
P1.04-113:
Nonclinical Development of PF-06439535, a Potential Biosimilar to
Bevacizumab
Julie A. Rosenberg, USA
P1.04-114:
Effect of Interleukin-2 Treatment Combined with Magnetic Fluid Hyperthermia
on Lewis Lung Cancer-Bearing Mice
Runlei Hu, China
P1.04-115:
Chemoterapy and Targeted Therapy Sensitivity Testing in Malignant Pleural
Effusions
Atila Akkoclu, Turkey
P1.04-116:
The Role of JAK/STAT3 Signaling Pathway on Apoptosis of Lung
Adenocarcinoma Cell Line PC-9 Induced by Icotinib
P1.05 PREVENTION AND TOBACCO CONTROL
P1.05-001:
Rural Tobacco Smoke Pollution: Preliminary Results of a Longitudinal Study
Kelly Buettner-Schmidt, USA
P1.05-002:
Comparative Study regarding Perception of Japanese Tobacco-Related Disease
Risk Warning Package Message
Tomoyasu Uno, Japan
P1.05-003:
Dutch Government Taken to Court by 2 Chest Physicians Because of Violation
WHO FCTC 5.3
Wanda de Kanter, Netherlands
P1.05-004:
Smoking Prevention Intervention with School Classes at a University Hospital
by Thoracic Surgeon and Pulmonologist
Sven Hillinger, Switzerland
P1.05-005:
Italian Multicentric Survey on Smoking Cessation in Lung Disease Patients and
the Role of Healthcare Workers in This Contest
Stefania Vallone, Italy
P1.05-006:
One Cigarette Takes 12.6 Minutes of Your Life
Erik Thunnissen, Netherlands
P1.05-007:
One-Stop Counselling, Social Support & Stop Smoking Aids Helps Smokers Quit
Emmanuel Odiase, Nigeria
P1.05-008:
Big Tobacco and the Creation of an Epidemic of Smoking-Related
Adenocarcinoma of the Lung: SEER-Based Analysis, 1973-2011
Gary Strauss, USA
P1.05-009:
EGCG Regulated Ku70 Acetylation for Apoptosis in Human Lung Cancer A549
Cells
Min Li, China
P1.06 SCREENING AND EARLY DETECTION
P1.06 SCREENING AND EARLY DETECTION – CT SCREENING PROGRAMS AND IMAGING
P1.06-001:
Ultra-Low Dose-CT Accurately Detects Significant Lung Nodules with a Fraction
of the Radiation of Conventional Low Dose-CT
Alistair Miller, Australia
P1.06-002:
Lung Cancer Screening Guidelines May Not Capture the Complete Population
At-Risk
April Plank, USA
P1.06-003:
Low-Dose CT Lung Cancer Screening in the Community: A Prospective Cohort
Study Incorporating a Gene-Based Lung Cancer Risk Test
Robert Young, New Zealand
P1.06-004:
Common Misconceptions About Lung Cancer Screening: A Nationwide Survey
Jean-François Morere, France
P1.06-005:
The Correlation between Visceral Pleural Invasion in T1a Non-Small Lung
Cancer and Lymph Node Metastasis
Mitsuhiro Tsuboi, Japan
P1.06 SCREENING AND EARLY DETECTION – BIOMARKERS
P1.06-006:
Metabolomics by NMR Facilitates the Non-Invasive Diagnosis and Staging of
NSCLC
Clara Pérez-Rambla, Spain
P1.06-007:
Plasma Circulating MicroRNA-944 and MicroRNA-3662 as Novel Histologic
Type-Specific Lung Cancer Biomarkers
Tomasz Powrózek, Poland
P1.06-008:
Functional Polymorphisms in PD-L1 Gene Are Associated with the Prognosis of
Patients with Early Stage Non-Small Cell Lung Cancer
Deuk Kju Jung, South Korea
P1.06-009:
Volatolomic Signatures to Assess Sensitivity to FGFR Tyrosine Kinase Inhibitors
Regina Kwon, USA
P1.06-010:
Allelic Heterogeneity and Its Role in Identifying Non-Small Cell Lung Cancer
Phenotypes
Lisa M. Alley, USA
P1.06-011:
miR-126 Is a Potential Diagnostic Marker for Malignant Pulmonary Nodules in
Endobronchial Epithelial Lining Fluid
Nicolas Kahn, Germany
P1.06-012:
Components of Serum Peptidome Can Differentiate between Healthy Controls
and Patients with Early Stage Lung Cancer
Piotr Widlak, Poland
P1.06 SCREENING AND EARLY DETECTION – RISK, HEALTH CARE DELIVERY, MISCELLANEOUS, CASE
REPORTS AND SERIES
P1.06-013:
Delays of Diagnosis and Treatment of Lung Cancer in a Populous Region of
Brazil
Fernando C. Abrão, Brazil
P1.06-014:
Impact of Surgery for Stage I Non-Small Cell Lung Cancer on Quality of Life
Emanuela Taioli, USA
P1.06-015:
A Population Based Study on Pulmonary Carcinoids in Iceland: Epidemiology,
Diagnosis and Survival Over Sixty Years
Astridur Petursdottir, Iceland
P1.06-016:
A Novel Functional Polymorphism in CIR1 Gene Is Associated with the Risk of
Lung Cancer
Chengcheng Jin, South Korea
P1.06-017:
Small Cell Lung Cancer in Lung Cancer Screening: Frequency and Outcome
Stefano Sestini, Italy
P1.06-018:
Can 30-Mortality after Lung Cancer Resection Be Used as an Individual
Surgeon Quality Outcome Internationally? National Data from the UK
Chiara Proli, United Kingdom
P1.06-019:
A Comparison of Demographic Risk Variables for Lung Cancer in New Zealand
Europeans and Maori: Are Maori More Susceptible to the Effects of Smoking?
Raewyn J. Hopkins, New Zealand
P1.06-020:
Detection of Aberrant ALK Expression from Circulating Tumor Cells for
Accurate Monitoring of ALK Driven NSCLC
Kasey D. Lawrence, USA
P1.06 SCREENING AND EARLY DETECTION – DIAGNOSTIC WORKUP
P1.06-021:
Is Safe to Follow High-Risk Patients with Suspicious Lung Nodules without
Invasive Tests?
André Luiz C. Trajano, Brazil
P1.06-022:
The British Thoracic Society Guideline on the Investigation and Management
of Pulmonary Nodules (2015)
David R. Baldwin, United Kingdom
P1.06-023:
Addition of Low Dose Computed Tomography Image-Features Improves
Diagnostic Accuracy for Indeterminate Pulmonary Nodules
Roshni Bhagalia, USA
P1.06-024:
Patterns of 18F FDG-PET/CT Studies in Patients with Suspected or Confirmed
Lung Cancer - A Johannesburg Academic Hospital Perspective
Olusegun A. Ayeni, South Africa
P1.06-025:
Statistical Analysis of 18F-FDG-PET/CT Findings of Ground Glass Nodule (GGN)
Kazuya Nishii, Japan
P1.06-026:
18F-FDG PET/CT Evaluation of Non-Small Cell Lung Cancer - Initial Experience
from Johannesburg
Osayande Evbuomwan, South Africa
P1.06 SCREENING AND EARLY DETECTION – PROGNOSTIC MARKERS
P1.06-027:
Role of Brain MRI and PET-CT in Follow-Up after Lung Cancer Surgery
Akira Sakurada, Japan
P1.06-028:
Distribution of Stage, Surgical Methods and Prognosis of Lung
Adenocarcinoma According to the Initial Diagnostic Patterns
Hyo-Jun Jang, South Korea
P1.06-029:
Serum Glutathione Peroxidase 3 as a Biomarker of Postoperative Relapse in
Patients with Lung Cancer
In-Jae Oh, South Korea
P1.07 SMALL CELL LUNG CANCER
P1.07 SMALL CELL LUNG CANCER - BIOLOGY
P1.07-001:
Preoperative Serum proGRP as a Predictor for Lung Tumor Histology
Marius Lund-Iversen, Norway
P1.07-002:
FAK Inhibition by PF228 Has Anti-Tumoral Effects Associated with Inhibition of
Histone 3 and Aurora Kinases A/B Phosphorylation in SCLC
Sebahat Ocak, Belgium
P1.07-003:
Role of Tumor Infiltrating Lymphocytes in Small Cell Lung Cancer
Inderjit Mehmi, USA
P1.07 SMALL CELL LUNG CANCER – EXTENSIVE DISEASE
P1.07-004:
Efficacy of Endostar Combined with Chemotherapy and Endostar Maintenance
Treatment for Patients with Extensive Small-Cell Lung Cancer
Li Chen, China
P1.07-005:
Paclitaxel and Irinotecan in Platinum Refractory/Resistant Small Cell Lung
Cancer: Final Analisis of One Galician Lung Cancer Group Experience
Sergio Vzsquez-Estevez, Spain
P1.07-006:
Final Results of Randomized Phase II Study of Carboplatin plus Irinotecan vs.
Carboplatin plus Amrubicin for ED-SCLC
Yuka Fujita, Japan
P1.07-007:
Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: The
Ottawa Hospital Experience
Andrew Bang, Canada
P1.07-008:
Preliminary Results from a Phase Ib/II Trial of Belotecan plus Ifosfamide in
Patients with Extensive-Stage Small-Cell Lung Cancer
Eun Kyung Cho, South Korea
P1.07 SMALL CELL LUNG CANCER – LIMITED DISEASE
P1.07-009:
Effect of Accurate Heart Outlining on Cardiac Dose - the CONVERT Trial
Experience
Corinne Faivre-Finn, United Kingdom
P1.07-010:
Hyperfractionated Versus Hypofractionated Radiotherapy for Limited-Stage
SCLC: A Retrospective Comparison of Two Prospective Studies
Ming Chen, China
P1.07-011:
"Peripheral Limited" Small Cell Lung Cancer (SCLC). Does Surgical Resection
Have a Role in Primary Management?
Mathew A. Vandeusen, USA
P1.07-012:
Hypo- or Conventionally Fractionated Radiotherapy in Patients with Limited
Stage Small Cell Lung Cancer (LS-SCLC): A Retrospective Analysis
Min Fan, China
P1.07 SMALL CELL LUNG CANCER – PROGNOSIS, EPIDEMIOLOGY AND OTHER
P1.07-013:
Real-Life 2-Year Therapeutic Strategies in the Management of 525 Small-Cell
Lung Cancers: The ESCAP Study Preliminary Results
Didier Debieuvre, France
P1.07-014:
Predictors of Survival in Small Cell Lung Cancer (SCLC) Patients (pts) < 50 Years
of Age: Results from the California Cancer Registry (CCR)
Joshua D. Lara, USA
P1.07-015:
The Prognostic Value of the Neutrophil Lymphocyte Ratio in Patients with
Small Cell Lung Cancer
Harjot Kaur, USA
P1.07-016:
Comparison of PET/CT, 99mTc-MDP Bone Scan and Serum Alkaline
Phosphatase for Detecting Bony Metastasis in Patients with Small Cell Lung
Cancer
Min Fan, China
P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES
P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES - MESOTHELIOMA
P1.08-001:
Rituximab for Treatment of Lymphoma Induced Marked Regression of
Malignant Mesothelioma with Dynamic Changes of Serum Cytokine Profiles
Keisuke Aoe, Japan
P1.08-002:
Stat3 Is a Potential Target for Malignant Pleural Mesothelioma (MPM)
Treatment
Seiji Matsumoto, Japan
P1.08-003:
Minimal Asbestos Exposure in Germline BAP1 Heterozygous Mice Is
Associated with Deregulated Inflammatory Response and Increased Risk of
MM
Andrea Napolitano, USA
P1.08-004:
Aki1 as a Potential Therapeutics Target in CREB1 Signaling in Malignant
Mesothelioma
Tadaaki Yamada, USA
P1.08-005:
Met and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in
Malignant Pleural Mesothelioma
Rajani Kanteti, USA
P1.08-006:
Lung Toxicity after Post-Operative Radiotherapy after EPP for Mesothelioma
and Pneumonectomy for Non-Small Cell Lung Cancer
Dirk De Ruysscher, Belgium
P1.08-007:
Programmed Cell Death 1 Ligand 1 (PD-L1) Expression in Thymoma
Shintaro Yokoyama, Japan
P1.08-008:
Efficacy of Palliative Chemotherapy in Malignant Pleural Mesothelioma from
Spanish BEMME Database. The Spanish Lung Cancer Group (SLCG)
Jordi Remon, Spain
P1.08-009:
Hepatocyte Growth Factor (HGF) Expression in Malignant Mesothelioma: A
Potential Predictive Marker for met/HGF-Targeted Therapy?
Peter B. Illei, USA
P1.08-010:
Understanding the Genetic Landscape of Malignant Mesothelioma - A
Comparison of Human and Murine Mesothelioma Cell Lines
Jenette Creaney, Australia
P1.08-011:
Clinical Outcome and Prognostic Factors for Advanced Malignant
Mesothelioma (MM) Patients (pts) Treated on Phase I Trials
Timothy A. Yap, United Kingdom
P1.08-012:
Immunohistochemistry as Prognostic Markers for Malignant Pleural
Mesothelioma
Taiichiro Otsuki, Japan
P1.08-013:
Long Non-Coding RNAs Associated with Lysine Demethylases Are
Overexpressed and Epigenetically Regulated in Malignant Pleural
Mesothelioma
Steven G. Gray, Ireland
P1.08-014:
The Small Molecule Inhibitor, LCRF004, Is Effective in Targeting the
RON/MST1R Pathway in Malignant Pleural Mesothelioma
Anne-Marie Baird, Australia
P1.08-015:
Malignant Pleural Mesothelioma: Observational and Retrospective Analysis of
Spanish Database (BEMME). The Spanish Lung Cancer Group (SLCG)
Noemi Reguart, Spain
P1.08-016:
Ponatinib Shows Promise in Malignant Pleural Mesothelioma Cells with Abl
Pathway Dysregulation
Hassan Lemjabbar-Alaoui, USA
P1.08-017:
microRNAs Expression in Malignant Pleural Mesothelioma, Asbestosis and
Benign Pulmonary Disease
Luca Ampollini, Italy
P1.08-018:
Spontaneous Regression of Mesothelioma
Gunnar N. Hillerdal, Sweden
P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES – OTHER THORACIC
MALIGNANCIES
P1.08-019:
Pure Bronchoplasty without Lung Parenchyma Resection for Central Carcinoid
Oleg Pikin, Russia
P1.08-020:
Survival Impact of Adjuvant Radiation and Chemotherapy in Patients with
Typical and Atypical Pulmonary Carcinoids
Lindsay M. Hannan, USA
P1.08-021:
Role of Surgery in Sarcomatoid Tumors of the Lung: A Multicentre Analysis
Tommaso Ricchetti, Italy
P1.08-022:
Intraoperative Brachytherapy for Thoracic Malignancies Resected with Close
or Positive Margins
Andreas Rimner, USA
P1.08-023:
Induction Chemotherapy Increases the Survival of Patients with Primary
Neuroectodermal Tumors of the Thorax
Akif Turna, Turkey
P1.08-024:
Large Cell Neuroendocrine Carcinoma: How Accurate Are the WHO 2004
Classification Criteria Applied?
Jules L. Derks, Netherlands
P1.08-025:
Tumor Control of Advanced Pulmonary Neuroendocrine Tumors (Carcinoids)
with Somatostatin Analogs: Experience at Gustave Roussy
Ivana Sullivan, France
P1.08-026:
First Case of SMARCB1(INI1)- Deficient Squamous Cell Carcinoma of the Pleura
Kazushi Yoshida, Japan
P1.08-027:
Clinicopathologic Study and Prognostic Analysis of Bronchial Mucoepidermoid
Carcinoma
Jian Ni, China
P1.08-028:
PD-L1 Expression in Neuroendocrine Tumors of the Lung
Kenjiro Tsuruoka, Japan
P1.08-029:
Combination Treatment of Intrathoracic Esofageal Cancer
Olga Lebedieva, Ukraine
P1.08-030:
Increasing the Interval between Neoadjuvant Chemoradiotherapy and Surgery
in Esophageal Cancer. A Meta-Analysis of Published Studies
Yaping Xu, China
P1.08-031:
Induction of Protein Citrullination and Auto-Antibodies Production in Murine
Exposed to Nickel Nanomaterials
Steven G. Gray, Ireland
P1.08-032:
Primary Pulmonary Lymphoma: Clinical Analysis of 34 Cases
Narjust Duma, USA
P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES - THYMOMA
P1.08-033:
pRb and p16INK4 in Human Thymic Epithelial Tumors in Relation to Human
Polyomavirus 7
Jos Maessen, Netherlands
P1.08-034:
The Clinicopathological Significance of PD-L1 Expression in Thymoma
Yohei Takumi, Japan
P1.08-035:
Pan-European Survey on Thymic Malignancies: A Collaboration of the EORTC
Lung Cancer Group (LCG) with the RYTHMIC Network
Jessica Menis, Belgium
P1.08-036:
Long-Term Survival after Surgical Treatment for Thymic Carcinoma
Hao Fu, China
P1.08-037:
PD-L1 Expression in Surgically Resected Thymic Epithelial Tumor
Myung-Ju Ahn, South Korea
P1.08-038:
The Effect of the WHO Histologic Classification on Thymic Specific Survival and
Overall Survival
Karl Uy, USA
P1.08-039:
Adjuvant Treatment of Thymic Carcinoma
Yen-Han Tseng, Taiwan
P1.10 ADVOCACY
P1.10-001:
EGFR Mutation Testing Patterns and Results in Brazil and the Need for Greater
Public Health Awareness of Molecular Testing
Gilberto De Lima Lopes, Brazil
P1.10-002:
Lung Cancer Patients' Perspectives on Multi-Disciplinary Care in a Community
Setting
Orion Osborne, USA
P1.10-003:
Lung Cancer in Ireland 2010 - 2015 - Are We Making Progress?
Aoife McNamara, Ireland
P1.10-004:
Novel Survey to Identify Single Greatest Challenge for Lung Cancer Patients
and Carers
Aoife McNamara, Ireland
P1.10-005:
Immunotherapy, What Lung Cancer and Melanoma Patients ...and Physicians,
Know
P1.10-006:
Defining a Standard Set of Patient-Centered Outcomes for Patients with Lung
Cancer
Jan P. Van Meerbeeck, Belgium
P1.10-007:
Impact of Intensive Interprofessional Perioperative Management on Clinical
Outcome in the Elderly Patients with Lung Cancer Surgery
Hidejiro Torigoe, Japan & Marko Jakopovic, Croatia
P1.11 PALLIATIVE AND SUPPORTIVE CARE
P1.11-001:
Short Form Chronic Respiratory Questionnaire Validation in a Lung Cancer
Population
Alex Molasiotis, Hong Kong
P1.11-002:
The Impact of Gastric Acid Suppressive Therapy on Treatment Outcomes of
EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Nesaretnam B. Kumarakulasinghe, Singapore
P1.11-003:
New Clinical and Biologic Insight Into Lung Cancer-Associated Cachexia From a
Large Cohort Study
Puneeth Iyengar, USA
P1.11-004:
Impact of Lung Cancer Surgery on Quality of Life of Family Caregivers
Dan J. Raz, USA
P1.11-005:
Enhancing Evaluation of Cancer Cachexia in Patients with NSCLC by Assessing
Change in Skeletal Muscle Mass at the L1 Level on Routine Chest CT
Jose N. Galeas, USA
P1.11-006:
Association between Nutritional Status Variables and Fatigue Diagnosis in
Patients with Non Small Cells Lung Cancer
Martha De La Torre-Vallejo, Mexico
P1.11-007:
To Determine Whether Psychosocial Factors Predict Depression among Older
Indian Lung Cancer Patients
Gouri Shankar Bhattacharyya, India
P1.11-008:
What Happens to the Pleural Space Affected by Malignant Effusion after
Bedside Pleurodesis?
Ricardo M. Terra, Brazil
P1.11-009:
Predictors of Hospital Discharge in Cancer Patients with Pericardial Effusion
Who Undergo Surgical Pericardial Drainage
Ricardo M. Terra, Brazil
P1.11-010:
Therapeutic and Supportive Care Unmet Needs in Lung Cancer Patients
Ronak Savla, USA
P1.11-011:
Taste Disorder in Patients with Thoracic Malignancy Who Received
Chemotherapy
Keisuke Azuma, Japan
P1.11-012:
Process for Developing a Rapid Tissue Donation Program in a Thoracic
Program: Ethical and Logistical Considerations
Matthew B. Schabath, USA
P1.11-013:
Place and Cause of Death in Patients with Lung Cancer in the United Kingdom
Emma L. O'Dowd, United Kingdom
P1.12 COMMUNITY PRACTICE
P1.12-001:
Trends in Accuracy and Comprehensiveness of Pathology Reports of Resected
Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Area of the US
Matthew P. Smeltzer, USA
P1.12-002:
International Online Tool for Therapeutic Decision Making in NSCLC (V2.0)
David R. Gandara, USA
P1.12-003:
Acquistion of and Early Clinical Results of Electromagnetic Navigational
Bronchoscopy for Diagnosis of Lung Cancer in a Community Setting
Royce Calhoun, USA
P1.12-004:
Early Results of Endobronchial Ultrasound for Lung Cancer Mediastinal Nodal
Staging in a Community Setting
Royce Calhoun, USA
P1.12-005:
Concomitant Electromagnetic Navigational Bronchoscopy and Endobronchial
Ultrasound to Diagnose and Stage Lung Cancer in a Community Setting
Royce Calhoun, USA
P1.12-006:
Factors That Influence Tobacco Consumption Among Portuguese Adolescents
Henrique Queiroga, Portugal
P1.12-007:
Thoracic Surgery Information on the Internet: Multilingual Quality Assessment
Stephen Barnett, Australia
P1.12-008:
Components of Creating and Implementing a Comprehensive Lung Cancer
Program in a Community Setting
Royce Calhoun, USA
P1.12-009:
Lung Cancer in Octogenarians
Ana Laura Ortega Granados, Spain
P1.12-010:
Bench to Bedside Detection of Actionable Genotypes by SNaPshot for Lung
Cancer Panel
Anuradha Choughule, India
P1.12-011:
Treatment Patterns and Overall Survival for Advanced NSCLC Following
Platinum-Based Chemotherapy in US Community Oncology Clinical Practice
Caroline McKay, USA

here - WCLC 2015

Transcription

Similar documents